A Placebo-Controlled Trial of Pioglitazone in Subjects with Nonalcoholic Steatohepatitis
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
BACKGROUND: No pharmacologic therapy has conclusively proved to be effective for the treatment of nonalcoholic steatohepatitis, which is characterized by insulin resistance, steatosis, and necroinflammation with or without centrilobular fibrosis. Pioglitazone is a thiazolidinedione that ameliorates insulin resistance and improves glucose and lipid metabolism in type 2 diabetes mellitus. METHODS: We randomly assigned 55 patients with impaired glucose tolerance or type 2 diabetes and liver biopsy-confirmed nonalcoholic steatohepatitis to 6 months of treatment with a hypocaloric diet (a reduction of 500 kcal per day in relation to the calculated daily intake required to maintain body weight) plus pioglitazone (45 mg daily) or a hypocaloric diet plus placebo. Before and after treatment, we assessed hepatic histologic features, hepatic fat content by means of magnetic resonance spectroscopy, and glucose turnover during an oral glucose tolerance test ([14C]glucose given with the oral glucose load and [3H]glucose given by intravenous infusion). RESULTS: Diet plus pioglitazone, as compared with diet plus placebo, improved glycemic control and glucose tolerance (P<0.001), normalized liver aminotransferase levels as it decreased plasma aspartate aminotransferase levels (by 40% vs. 21%, P=0.04), decreased alanine aminotransferase levels (by 58% vs. 34%, P<0.001), decreased hepatic fat content (by 54% vs. 0%, P<0.001), and increased hepatic insulin sensitivity (by 48% vs. 14%, P=0.008). Administration of pioglitazone, as compared with placebo, was associated with improvement in histologic findings with regard to steatosis (P=0.003), ballooning necrosis (P=0.02), and inflammation (P=0.008). Subjects in the pioglitazone group had a greater reduction in necroinflammation (85% vs. 38%, P=0.001), but the reduction in fibrosis did not differ significantly from that in the placebo group (P=0.08). Fatigue and mild lower-extremity edema developed in one subject who received pioglitazone; no other adverse events were observed. CONCLUSIONS: In this proof-of-concept study, the administration of pioglitazone led to metabolic and histologic improvement in subjects with nonalcoholic steatohepatitis. Larger controlled trials of longer duration are warranted to assess the long-term clinical benefit of pioglitazone. (ClinicalTrials.gov number, NCT00227110 [ClinicalTrials.gov] .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Significant improvements were observed in hepatic steatosis, hepatocellular ballooning, necrosis, and inflammation; however, fibrosis reduction did not reach statistical significance compared with placebo.”
From Strategies to promote liver fibrosis amelioration with involvement of restorative macrophages (2026) · cites this paper as [202]
In the citing paper
“Accruing randomized clinical trial data suggest that pioglitazone, GLP-1 RA, and a dual GIP and GLP-1 RA have potential benefits in terms of decreasing hepatic steatosis and in the resolution of MASH without worsening of fibrosis in individuals with biopsy-proven MASH or those at higher risk of clinically significant liver fibrosis identified with noninvasive tests (146-153).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [146]
In the citing paper
“Treatment with exenatide reduced liver steatosis [109,146,150] and when added to pioglitazone, an oral hypoglycemic and insulin sensitizing drug approved for the treatment of T2D that acts on nuclear peroxisome proliferator activated receptor-gamma (PPAR-γ) [147], potentiated the known action of pioglitazone in reducing hepatic fat [92].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [92]
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Role of AMP-Activated Protein Kinase in Mechanism of Metformin Action
Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13505 · Cited by 5,652
Matsuda, M., & DeFronzo, R. A. (1999) · Diabetes Care · doi:10.2337/diacare.22.9.1462 · Cited by 5,621
Self-citationYamauchi, T., Kamon, J., Minokoshi, Y., Ito, Y., Waki, H., Uchida, S., Yamashita, S., Noda, M., Kita, S., Ueki, K., et al. (2002) · Nature Medicine · doi:10.1038/nm788 · Cited by 4,238
Prevalence of Hepatic Steatosis in An Urban Population in the United States: Impact of Ethnicity
Browning, J. D., Szczepaniak, L. S., Dobbins, R., Nuremberg, P., Horton, J. D., Cohen, J. C., Grundy, S. M., & Hobbs, H. H. (2004) · Hepatology · doi:10.1002/hep.20466 · Cited by 3,664
Sampling Variability of Liver Biopsy in Nonalcoholic Fatty Liver Disease
Ratziu, V., Charlotte, F., Heurtier, A., Gombert, S., Giral, P., Bruckert, E., Grimaldi, A., Capron, F., & Poynard, T. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.03.084 · Cited by 2,106
Molecular mediators of hepatic steatosis and liver injury
Browning, J. D., & Horton, J. D. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200422422 · Cited by 1,772
Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease
Samuel, V. T., Liu, Z.-X., Qu, X., Elder, B. D., Bilz, S., Befroy, D., Romanelli, A. J., & Shulman, G. I. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m313478200 · Cited by 1,322
Xu, A., Wang, Y., Keshaw, H., Xu, L. Y., Lam, K. S. L., & Cooper, G. J. S. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200317797 · Cited by 1,298
Xu, A., Wang, Y., Keshaw, H., Xu, L. Y., Lam, K. S. L., & Cooper, G. J. S. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17797 · Cited by 1,296
Research works printed but not linked: 3
- 10.1111/j.1572-0241.2003.08699.x · doi:10.1111/j.1572-0241.2003.08699.x · Paper page
- 10.1210/jc.87.6.2784 · doi:10.1210/jc.87.6.2784 · Paper page
- 10.1172/JCI22422 · DOI · Paper page
Cited by
Items 301–400 of 1,003
Liver diseases and metabolic syndrome
Watanabe, S., Yaginuma, R., Ikejima, K., & Miyazaki, A. (2008) · Journal of Gastroenterology · doi:10.1007/s00535-008-2193-6 · Cited by 176
“Interestingly, a recent prospective study has shown that histological features in patients with NASH; including hepatic steatosis, ballooning necrosis, and infl ammation, are improved by administrating pioglitazone as compared with placebo.(110) However, fatigue and mild lowerextremity edema developed in 1 of 55 subje…”
BackgroundNonalcoholic Fatty Liver Disease: Current Issues and Novel Treatment Approaches
Lomonaco, R., Sunny, N. E., Bril, F., & Cusi, K. (2013) · Drugs · doi:10.1007/s40265-012-0004-0 · Cited by 158
“with T2DM although it has been only tested in a short-term study [12].”
BackgroundSelf-citationSangro, P., de la Torre‐Aláez, M., Sangro, B., & D’Avola, D. (2023) · Journal of Physiology and Biochemistry · doi:10.1007/s13105-023-00954-4 · Cited by 180
“However, the effect on liver fibrosis was not significant, although worsening of liver fibrosis was not observed [33–35].”
BackgroundNon-Alcoholic Fatty Liver Disease
Weiß, J., Rau, M., & Geier, A. (2014) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2014.0447 · Cited by 155
Nonalcoholic Fatty Liver Disease in Women
Suzuki, A., & Abdelmalek, M. F. (2009) · Women's Health · doi:10.2217/17455057.5.2.191 · Cited by 154
Witjes, J. J., Smits, L. P., Pekmez, C. T., Prodan, A., Meijnikman, A. S., Troelstra, M. A., Bouter, K. E. C., Herrema, H., Levin, E., Holleboom, A. G., et al. (2020) · Hepatology Communications · doi:10.1002/hep4.1601 · Cited by 153
“,(28) in which treatment with pioglitazone in individuals with NASH led to a 54% reduction of steatosis compared with placebo, we performed a power analysis to calculate the number of participants necessary to detect a 25% reduction in our primary outcome parameter, reversal of steatosis, and necro-inflammation follow…”
MethodNon-alcoholic Fatty Liver Disease: A Clinical Update
Pappachan, J. M., Babu, S., Krishnan, B., & Ravindran, N. C. (2017) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2017.00013 · Cited by 154
Kita, Y., Takamura, T., Misu, H., Ota, T., Kurita, S., Takeshita, Y., Uno, M., Matsuzawa-Nagata, N., Kato, K.-I., Ando, H., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0043056 · Cited by 152
Sitagliptin in patients with non-alcoholic steatohepatitis: A randomized, placebo-controlled trial
Joy, T. R., McKenzie, C. A., Tirona, R. G., Summers, K., Seney, S., Chakrabarti, S., Malhotra, N., & Beaton, M. D. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i1.141 · Cited by 152
Dupuis, L., Dengler, R., Heneka, M. T., Meyer, T., Zierz, S., Kassubek, J., Fischer, W., Steiner, F., Lindauer, E., Otto, M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0037885 · Cited by 151
“Pioglitazone displays pleiotropic effects on energy metabolism through insulin sensitization, decreased glycaemia, and decreased circulating levels of liver enzymes and has been shown to be safe even in non-diabetic patients [7,8,9,10].”
BackgroundXia, M., Yan, H., He, W., Li, X., Li, C., Yao, X., Li, R., Zeng, M., & Gao, X. (2012) · Obesity · doi:10.1038/oby.2011.302 · Cited by 165
“Several clinical trials (34,35) on NAFLD have used spectroscopic magnetic resonance as an outcome measure.”
BackgroundBae, J. S., Lee, D. H., Lee, J. Y., Kim, H., Yu, S. J., Lee, J., Cho, E. J., Lee, Y. B., Han, J. K., & Choi, B. I. (2019) · European Radiology · doi:10.1007/s00330-019-06272-y · Cited by 163
Genetic Factors in the Pathogenesis of Nonalcoholic Fatty Liver and Steatohepatitis
Dongiovanni, P., Romeo, S., & Valenti, L. (2015) · BioMed Research International · doi:10.1155/2015/460190 · Cited by 150
“Pharmacological activation of PPARγ improves insulin resistance in diabetes and decreases steatosis in NAFLD patients by restoring adipose tissue insulin sensitivity and adiponectin release [105, 106].”
BackgroundJuluri, R., Vuppalanchi, R., Olson, J., Ünalp, A., Van Natta, M. L., Cummings, O. W., Tonascia, J., & Chalasani, N. (2011) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e3181dd1348 · Cited by 148
Kallwitz, E. R., McLachlan, A., & Cotler, S. J. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.22 · Cited by 150
ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Cusi, K. J., Ekhlaspour, L., Fleming, T. K., Hilliard, M. E., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc24-s004 · Cited by 258
Self-citationNonalcoholic Fatty Liver Disease
Bril, F., & Cusi, K. J. (2016) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2016.06.005 · Cited by 169
Self-citationColetta, D. K., Sriwijitkamol, A., Wajcberg, E., Tantiwong, P., Li, M., Prentki, M., Madiraju, M., Jenkinson, C. P., Cersosimo, E., Musi, N., et al. (2009) · Diabetologia · doi:10.1007/s00125-008-1256-9 · Cited by 148
“Activation of PPARG alters the expression of many genes [7, 8], resulting in enhanced insulin sensitivity in liver and muscle [9, 10], reduced intracellular lipid content in liver and muscle [11, 12], and increased insulin receptor signalling in type 2 diabetes [13, 14].”
Self-citationMetabolic Impact of Nonalcoholic Steatohepatitis in Obese Patients With Type 2 Diabetes
Lomonaco, R., Bril, F., Portillo-Sanchez, P., Ortiz-Lopez, C., Orsak, B., Biernacki, D., Lo, M., Suman, A., Weber, M. H., & Cusi, K. (2016) · Diabetes Care · doi:10.2337/dc15-1876 · Cited by 146
“glycerides, we acquired localized proton nuclear magnetic resonance spectra of the liver using methodology previously described (5,22,23).”
Self-citationSun, C., Huang, F., LIU, X., Xiao, X., Yang, M., Hu, G. M., Liu, H., & Liao, L. (2015) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2015.2076 · Cited by 158
“The concentration of free fatty acids (FFA) used in the experiments was similar to the fasting FFA plasma concentrations observed in human NASH, ranging from 700 to 1,000 μM (18-21).”
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s004 · Cited by 147
Nuclear receptors as therapeutic targets in cholestatic liver diseases
Zollner, G., & Trauner, M. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2008.00030.x · Cited by 146
“These drugs show beneficial effects in non-alcoholic fatty liver disease and do not seem to lead to liver injury in patients with fatty liver and increased baseline liver function tests (Belfort et al., 2006; Caldwell et al., 2006).”
Mitochondrial dysfunction, insulin resistance, and type 2 diabetes mellitus
Abdul-Ghani, M. A., & DeFronzo, R. A. (2008) · Current Diabetes Reports · doi:10.1007/s11892-008-0030-1 · Cited by 146
Self-citationThe impact of liver fat vs visceral fat in determining categories of prediabetes
Kantartzis, K., Machann, J., Schick, F., Fritsche, A., Häring, H., & Stefan, N. (2010) · Diabetologia · doi:10.1007/s00125-010-1663-6 · Cited by 156
“While treatment with thiazolidinediones is associated with a reduction in both liver and visceral fat content but with an increase in total-body fat [48], targeting peroxisome proliferator-activated receptor (PPAR)-δ appears to have specific effects on liver fat.”
BackgroundBARSHOP, N. J., SIRLIN, C. B., SCHWIMMER, J. B., & LAVINE, J. E. (2008) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03703.x · Cited by 145
Noninvasive Assessment of Hepatic Steatosis
Mazhar, S. M., Shiehmorteza, M., & Sirlin, C. B. (2008) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2008.11.023 · Cited by 156
Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived?
Abdul-Ghani, M., DeFronzo, R. A., Del Prato, S., Chilton, R., Singh, R., & Ryder, R. E. J. (2017) · Diabetes Care · doi:10.2337/dc16-2736 · Cited by 145
Self-citationRevision and update on clinical practice guideline for liver cirrhosis
Suk, K. T., Baik, S. K., Yoon, J., Cheong, J. Y., Paik, Y. H., Lee, C. H., Kim, Y. S., Lee, J. W., Kim, D. J., Cho, S. W., et al. (2012) · The Korean Journal of Hepatology · doi:10.3350/kjhep.2012.18.1.1 · Cited by 148
Genetic determinants of hepatic steatosis in man
Hooper, A. J., Adams, L. A., & Burnett, J. R. (2011) · Journal of Lipid Research · doi:10.1194/jlr.r008896 · Cited by 142
Fougerat, A., Montagner, A., Loiseau, N., Guillou, H., & Wahli, W. (2020) · Cells · doi:10.3390/cells9071638 · Cited by 156
Mathew, M., Tay, E., & Cusi, K. (2010) · Cardiovascular Diabetology · doi:10.1186/1475-2840-9-9 · Cited by 142
“Endothelial dysfunction has been reported to be reversible with lifestyle changes [60], anti-inflammatory agents such as salicylates [61] or by insulin-sensitizers such as thiazolidinediones [62].”
BackgroundSelf-citationPortincasa, P., Khalil, M., Mahdi, L., Perniola, V., Idone, V., Graziani, A., Baffy, G., & Ciaula, A. D. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25115640 · Cited by 183
“The effect on liver fibrosis was absent, and worsening of liver fibrosis was not observed [239–241].”
BackgroundTsochatzis, E. A., Papatheodoridis, G. V., & Archimandritis, A. J. (2009) · Mediators of Inflammation · doi:10.1155/2009/831670 · Cited by 141
“NASH lesions, also increases adiponectin levels providing indirect evidence of a potential adiponectin effect [97].”
BackgroundOhki, T., Isogawa, A., Iwamoto, M., Ohsugi, M., Yoshida, H., Toda, N., Tagawa, K., Omata, M., & Koike, K. (2012) · The Scientific World Journal · doi:10.1100/2012/496453 · Cited by 139
“Particularly, trials of glucose lowering agents such as metformin and pioglitazone have yielded promising results [18, 26].”
Use of mesenchymal stem cells to treat liver fibrosis: Current situation and future prospects
Berardis, S., Dwisthi Sattwika, P., Najimi, M., & Sokal, E. M. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i3.742 · Cited by 139
Shields, W. W., Thompson, K. E., Grice, G. A., Harrison, S. A., & Coyle, W. J. (2009) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x09105462 · Cited by 139
“55 patients with NASH treated for 6 months with pioglitazone [Belfort et al. 2006].”
BackgroundSelf-citationThe Future of Thiazolidinedione Therapy in the Management of Type 2 Diabetes Mellitus
Yau, H., Rivera, K., Lomonaco, R., & Cusi, K. J. (2013) · Current Diabetes Reports · doi:10.1007/s11892-013-0378-8 · Cited by 153
“[5] studied 55 patients with either IGT or T2DM and biopsy-proven NASH.”
BackgroundResultInfluentialSelf-citationMantovani, A., Byrne, C. D., Scorletti, E., Mantzoros, C. S., & Targher, G. (2020) · Diabetes & Metabolism · doi:10.1016/j.diabet.2019.12.007 · Cited by 138
Nonalcoholic Fatty Liver Disease and Type 2 Diabetes: Common Pathophysiologic Mechanisms
Saponaro, C., Gaggini, M., & Gastaldelli, A. (2015) · Current Diabetes Reports · doi:10.1007/s11892-015-0607-4 · Cited by 159
Self-citationCuthbertson, D. J., Shojaee-Moradie, F., Sprung, V. S., Jones, H., Pugh, C. J. A., Richardson, P., Kemp, G. J., Barrett, M., Jackson, N. C., Thomas, E. L., et al. (2016) · Clinical Science · doi:10.1042/cs20150447 · Cited by 138
Cusi, K. (2016) · Diabetologia · doi:10.1007/s00125-016-3952-1 · Cited by 137
“It has been about a decade since Belfort et al [42] first reported in a proof-of-concept study that in patients with NASH and either impaired glucose tolerance or type 2 diabetes, pioglitazone treatment significantly ameliorated hepatic steatosis and necroinflammation.”
BackgroundSelf-citationPeng, J., Li, Q., Li, K., Zhu, L., Lin, X., Lin, X., Shen, Q., Li, G., & Xie, X. S. (2017) · Journal of Diabetes Research · doi:10.1155/2017/3417306 · Cited by 141
“Patients with prediabetes or T2DM treated with pioglitazone experience a remarkable improvement in hepatic steatosis, and steatohepatitis can be cured within 6 months [32].”
BackgroundRetractedLipid metabolism in MASLD and MASH: From mechanism to the clinic
Carli, F., Della Pepa, G., Sabatini, S., Vidal Puig, A., & Gastaldelli, A. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101185 · Cited by 147
Self-citationLecoultre, V., Egli, L., Carrel, G., Theytaz, F., Kreis, R., Schneiter, P., Boss, A., Zwygart, K., Lê, K., Bortolotti, M., et al. (2013) · Obesity · doi:10.1002/oby.20377 · Cited by 135
“Although HISI was not decreased, this nonetheless indicates that glucose, as fructose, impaired hepatic insulin’s effects.”
BackgroundMethodInfluentialHan, M. A. T., Altayar, O., Hamdeh, S., Takyar, V., Rotman, Y., Etzion, O., Lefebvre, E., Safadi, R., Ratziu, V., Prokop, L. J., et al. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.06.011 · Cited by 135
Hepatic glucose metabolism in the steatotic liver
Scoditti, E., Sabatini, S., Carli, F., & Gastaldelli, A. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00888-8 · Cited by 134
“…EGP as well as Hep-IR in 434 Pima Native Americans without T2D 52 , a population at high risk of T2D and SLD. High fasting glucose, insulin, EGP and Hep-IR were also reported in individuals with MASH by Belfort and colleagues 53 and Saponaro and colleagues 54 ( n = 55 and n = 32, respectively).”
Self-citationClinical approaches to non-alcoholic fatty liver disease
Schwenger, K. J. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i7.1712 · Cited by 133
Death Receptor 5 Signaling Promotes Hepatocyte Lipoapoptosis
Cazanave, S. C., Mott, J. L., Bronk, S. F., Werneburg, N. W., Fingas, C. D., Meng, X. W., Finnberg, N., El-Deiry, W. S., Kaufmann, S. H., & Gores, G. J. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.280420 · Cited by 133
Kaji, K., Yoshiji, H., Ikenaka, Y., Noguchi, R., Aihara, Y., Douhara, A., Moriya, K., Kawaratani, H., Shirai, Y., Yoshii, J., et al. (2013) · Journal of Gastroenterology · doi:10.1007/s00535-013-0783-4 · Cited by 141
Tang, A., Rabasa-Lhoret, R., Castel, H., Wartelle-Bladou, C., Gilbert, G., Massicotte-Tisluck, K., Chartrand, G., Olivié, D., Julien, A.-S., de Guise, J., et al. (2015) · Diabetes Care · doi:10.2337/dc14-2548 · Cited by 133
“However, the 12-week duration of our study was sufficient to address our primary end point and was justified by the normalization of transaminases, another surrogate marker of treatment response, within this interval in a previous randomized trial evaluating the effect of a thiazolidinedione in patients with type 2 di…”
BackgroundKalra, S., Vithalani, M., Gulati, G., Kulkarni, C. M., Kadam, Y., Pallivathukkal, J. K., Das, B., Sahay, R. K., & Modi, K. D. (2013) · PubMed · Cited by 131
Lipid oxidation products in the pathogenesis of non-alcoholic steatohepatitis
Bellanti, F., Villani, R., Facciorusso, A., Vendemiale, G., & Serviddio, G. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.01.023 · Cited by 148
“Some studies have demonstrated an improvement in glucose and lipid metabolism, as well as hepatic inflammation and fat storage [215-217].”
Nonalcoholic Fatty Liver Disease (NAFLD). Mitochondria as Players and Targets of Therapies?
Ciaula, A. D., Passarella, S., Shanmugam, H., Noviello, M., Bonfrate, L., Wang, D. Q. ‐., & Portincasa, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22105375 · Cited by 154
“TZDs have an effect on NAFLD in patients [173,180,312] since pioglitazone [173,178–181] and rosiglitazone [185–187] improve NASH.”
BackgroundBreakthroughs in therapies for NASH and remaining challenges
Ratziu, V., Francque, S., & Sanyal, A. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.04.002 · Cited by 132
Metabolic Syndrome and Insulin Resistance: Perioperative Considerations
Bagry, H., Raghavendran, S., Carli, F., Warner, D. S., & Warner, M. A. A. (2008) · Anesthesiology · doi:10.1097/aln.0b013e3181649314 · Cited by 152
Recurrent Disease Following Liver Transplantation for Nonalcoholic Steatohepatitis Cirrhosis
Malik, S. M., deVera, M. E., Fontes, P., Shaikh, O., Sasatomi, E., & Ahmad, J. (2009) · Liver Transplantation · doi:10.1002/lt.21943 · Cited by 133
“NASH patients who developed recurrent disease were initially treated with a combination of vitamin C, vitamin E, and ursodiol(41) without obvious improvement, and 2 patients were started on pioglitazone after the recent study demonstrating its effectiveness in patients with NASH with or without insulin resistance.(42,…”
BackgroundHe, X.-X., Wu, X.-L., Chen, R.-P., Chen, C., Liu, X.-G., Wu, B.-J., & Huang, Z.-M. (2016) · PLOS ONE · doi:10.1371/journal.pone.0162368 · Cited by 129
Metformin versus dietary treatment in nonalcoholic hepatic steatosis: a randomized study
Garinis, G. A., Fruci, B., Mazza, A., Siena, M. D., Abenavoli, S., Gulletta, E., Ventura, V., Greco, M., Abenavoli, L., & Belfiore, A. (2010) · International Journal of Obesity · doi:10.1038/ijo.2010.40 · Cited by 134
In Vivo Actions of Peroxisome Proliferator–Activated Receptors
Eldor, R., DeFronzo, R. A., & Abdul-Ghani, M. (2013) · Diabetes Care · doi:10.2337/dcs13-2003 · Cited by 126
Self-citationLiver fat content determined by magnetic resonance imaging and spectroscopy
Springer, L., Machann, J., Claussen, C., Schick, F., & Schwenzer, N. F. (2010) · World Journal of Gastroenterology · doi:10.3748/wjg.v16.i13.1560 · Cited by 133
Li, J., Li, Y., Kong, L., & Hu, Q. (2010) · Hepatology · doi:10.1002/hep.23524 · Cited by 129
“High fructose consumption is a risk factor for NASH.1,2 The pathogenesis of fructose-induced hypertriglyceride- mia and hepatic steatosis is associated with insulin and/or leptin resistance.3-6 Fructose decreases tyrosine (Tyr) phosphorylation of insulin-induced insulin recep- tor substrate 1 (IRS1) and inhibits activ…”
BackgroundInfluentialEffect of canagliflozin on liver function tests in patients with type 2 diabetes
Leiter, L. A., Forst, T. M., Polidori, D., Balis, D. A., Xie, J., & Sha, S. (2015) · Diabetes & Metabolism · doi:10.1016/j.diabet.2015.10.003 · Cited by 136
Metabolic Spectrum of Liver Failure in Type 2 Diabetes and Obesity: From NAFLD to NASH to HCC
Kim, H.-M., Lee, D. S., An, T. H., Park, H., Kim, W. K., Bae, K., & Oh, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094495 · Cited by 146
“Pioglitazone, an anti-diabetic drug of thiazolidinedione-type, improves liver histology and increases adiponectin levels in patients with NASH [104,125].”
BackgroundEffects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes
Sathyanarayana, P., Jogi, M., Muthupillai, R., Krishnamurthy, R., Samson, S. L., & Bajaj, M. (2011) · Obesity · doi:10.1038/oby.2011.152 · Cited by 124
“However, recent placebo-controlled clinical trials have not shown a significant benefit of pioglitazone treatment on histologic hepatic fibrosis score in NASH patients (10,29).”
BackgroundResultInfluentialPediatric Nonalcoholic Fatty Liver Disease in 2009
Alisi, A., Manco, M., Vania, A., & Nobili, V. (2009) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2009.06.014 · Cited by 137
Ratziu, V., Sanyal, A. J., Loomba, R., Rinella, M., Harrison, S., Anstee, Q. M., Goodman, Z., Bedossa, P., MacConell, L., Shringarpure, R., et al. (2019) · Contemporary Clinical Trials · doi:10.1016/j.cct.2019.06.017 · Cited by 126
“A previous study demonstrated effects of pioglitazone on inflammation and liver cell injury in steatohepatitis in as little as 6 months; another study confirmed fibrosis reduction after only 6 months of treatment [29,30].”
Self-citationTakeshita, Y., Honda, M., Harada, K., Kita, Y., Takata, N., Tsujiguchi, H., Tanaka, T., Goto, H., Nakano, Y., Iida, N., et al. (2022) · Diabetes Care · doi:10.2337/dc21-2049 · Cited by 146
“Unexpectedly, the percentage of participants in the tofogliflozin group who had an improvement in steatosis, hepatocellular ballooning, and lobular inflammation in this trial (65, 55, and 50%, respectively) was not greater than that reported with liraglutide treatment (8), obeticholic acid treatment (45), and pioglita…”
BackgroundMethodResultDipeptidyl peptidase IV (DDP IV) in NASH patients
Balaban, Y. H., Korkusuz, P., Simsek, H., Gokcan, H., Gedikoglu, G., Pinar, A., Hascelik, G., Asan, E., Hamaloglu, E., & Tatar, G. (2007) · Annals of Hepatology · doi:10.1016/s1665-2681(19)31905-2 · Cited by 125
FXR Agonists as Therapeutic Agents for Non-alcoholic Fatty Liver Disease
Carr, R. M., & Reid, A. E. (2015) · Current Atherosclerosis Reports · doi:10.1007/s11883-015-0500-2 · Cited by 132
Emerging Molecular Targets for Treatment of Nonalcoholic Fatty Liver Disease
Chen, Z., Yu, Y., Cai, J., & Li, H. (2019) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2019.08.006 · Cited by 133
Pioglitazone for NAFLD Patients With Prediabetes or Type 2 Diabetes Mellitus: A Meta-Analysis
Lian, J., & Fu, J. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.615409 · Cited by 136
Impact of non‐alcoholic fatty liver disease on chronic hepatitis B
Bondini, S., Kallman, J. B., Wheeler, A., Prakash, S., Gramlich, T. L., Jondle, D. M., & Younossi, Z. M. (2007) · Liver International · doi:10.1111/j.1478-3231.2007.01482.x · Cited by 133
Leite, N. C., Villela-Nogueira, C. A., Cardoso, C. R. L., & Salles, G. F. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i26.8377 · Cited by 143
The Metabolic Syndrome and Its Influence on Nonalcoholic Steatohepatitis
Kanwar, P., & Kowdley, K. V. (2015) · Clinics in Liver Disease · doi:10.1016/j.cld.2015.10.002 · Cited by 141
Biopsy and Noninvasive Methods to Assess Progression of Nonalcoholic Fatty Liver Disease
Bédossa, P., & Patel, K. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.03.008 · Cited by 132
Preparing for the NASH Epidemic: A Call to Action
Kanwal, F., Shubrook, J. H., Younossi, Z. M., Natarajan, Y., Bugianesi, E., Rinella, M. E., Harrison, S. A., Mantzoros, C. S., Pfotenhauer, K. M., Klein, S., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.04.074 · Cited by 141
Self-citationNonalcoholic steatohepatitis: the therapeutic challenge of a global epidemic
Schattenberg, J. M., & Schuppan, D. (2011) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32834c7cfc · Cited by 119
IDILMAN, R., MIZRAK, D., CORAPCIOGLU, D., BEKTAS, M., DOGANAY, B., SAYKI, M., COBAN, S., ERDEN, E., SOYKAN, I., EMRAL, R., et al. (2008) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03723.x · Cited by 119
Treatment of non-alcoholic fatty liver disease.
(2007) · PubMed Central · Cited by 118
Willy, J. A., Young-Baird, S. K., Stevens, J. L., Masuoka, H. C., & Wek, R. C. (2015) · Molecular Biology of the Cell · doi:10.1091/mbc.e15-01-0036 · Cited by 141
“To determine whether the UPR is activated before saturated FFAinduced cell death, we measured markers of the UPR during a time course of exposure to physiological concentrations of free fatty acids (600 μM; Belfort et al., 2006; Koutsari and Jensen, 2006).”
Review article: diagnosis and treatment of non‐alcoholic fatty liver disease
OH, M. K., Winn, J., & Poordad, F. F. (2008) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03752.x · Cited by 137
Deivanayagam, S., Mohammed, B. S., Vitola, B. E., Naguib, G. H., Keshen, T. H., Kirk, E. P., & Klein, S. (2008) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/88.2.257 · Cited by 116
“Hepatic sensitivity was assessed by using the Hepatic Insulin Sensitivity Index (HISI), which is the inverse of the product of the basal hepatic glucose production rate (in mol kg FFM 1 min (1)) and the fasting plasma insulin concentration (in mU/L) (21, 22).”
MethodSt. George, A., Bauman, A., Johnston, A., Farrell, G., Chey, T., & George, J. (2009) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2008.05694.x · Cited by 117
Efficacy of insulin-sensitizing agents in nonalcoholic fatty liver disease
Omer, Z., Cetinkalp, S., Akyildiz, M., Yilmaz, F., Batur, Y., Yilmaz, C., & Akarca, U. (2010) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0b013e32832e2baf · Cited by 116
Adams, L. A., Crawford, D. H., Stuart, K. A., House, M. J., Pierre, T. G. S., Webb, M., Ching, H. L., Kava, J., Bynevelt, M., MacQuillan, G. C., et al. (2015) · Hepatology · doi:10.1002/hep.27662 · Cited by 124
Polyzos, S. A., Perakakis, N., & Mantzoros, C. S. (2019) · Metabolism · doi:10.1016/j.metabol.2019.05.001 · Cited by 115
“Likewise, TZDs increase body weight and fat in NASH patients without lipodystrophy [127].”
BackgroundResultSibony, R. W., Segev, O., Dor, S., & Raz, I. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242417147 · Cited by 167
“…levels, as it decreased plasma aspartate aminotransferase levels by 40% vs. 21% ( p = 0.04), decreased alanine aminotransferase levels by 58% vs. 34%, ( p 0.001), decreased hepatic fat content by 54% vs. 0% ( p 0.001), and increased hepatic insulin sensitivity by 48% vs. 14% ( p = 0.008) [27].”
BackgroundInfluentialGenetics of nonalcoholic fatty liver disease
Dongiovanni, P., & Valenti, L. V. C. (2015) · Metabolism · doi:10.1016/j.metabol.2015.08.018 · Cited by 135
“Pharmacological activation of PPARγ improves insulin resistance in diabetes and decreases steatosis by restoring adipose tissue insulin sensitivity and adiponectin release [114].”
BackgroundDoes nonalcoholic fatty liver disease cause cardiovascular disease? Current knowledge and gaps
Santos, R. D., Valenti, L. V. C., & Romeo, S. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.01.029 · Cited by 124
Nogueira, J. P., & Cusi, K. (2024) · Diabetes Spectrum · doi:10.2337/dsi23-0013 · Cited by 110
Self-citationStefan, N., Ramsauer, M., Jordan, P., Nowotny, B., Kantartzis, K., Machann, J., Hwang, J., Nowotny, P., KAHL, S., Harreiter, J., et al. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70170-0 · Cited by 120
Pharmacological management of nonalcoholic fatty liver disease
Barb, D., Portillo-Sanchez, P., & Cusi, K. (2016) · Metabolism · doi:10.1016/j.metabol.2016.04.004 · Cited by 114
Self-citationKASL clinical practice guidelines: Management of nonalcoholic fatty liver disease
(2013) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2013.19.4.325 · Cited by 125
Non-alcoholic fatty liver disease and insulin resistance: From bench to bedside
Gariani, K., Philippe, J., & Jornayvaz, F. R. (2013) · Diabetes & Metabolism · doi:10.1016/j.diabet.2012.11.002 · Cited by 113
“[20] Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, et al.”
BackgroundPοlyzos, S. A., & Mantzoros, C. S. (2016) · Metabolism · doi:10.1016/j.metabol.2016.05.013 · Cited by 116
“published the first relevant study in 2006 [29].”
BackgroundMethodResultInfluentialThiazolidinedione drugs in the treatment of type 2 diabetes mellitus: past, present and future
Davidson, M. A., Mattison, D. R., Azoulay, L., & Krewski, D. (2018) · Critical Reviews in Toxicology · doi:10.1080/10408444.2017.1351420 · Cited by 112
“The use of TZDs in the treatment of NASH has been explored in numerous clinical studies (e.g. NeuschwanderTetri et al. 2003; Promrat et al. 2004; Belfort et al. 2006; Aithal et al. 2008; Idilman et al. 2008; Ratziu et al. 2008; Sanyal et al. 2010), with differing results.”
BackgroundDixon, E. D., Nardo, A. D., Claudel, T., & Trauner, M. (2021) · Genes · doi:10.3390/genes12050645 · Cited by 125
Pioglitazone in the treatment of NASH: the role of adiponectin
Gastaldelli, A., Harrison, S., Belfort‐Aguiar, R., Hardies, J., Balas, B., Schenker, S., & Cusi, K. (2010) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2010.04405.x · Cited by 113
“One may speculate that the insulin-sensitizing effect of adiponectin may have not only reduced hepatic TG synthesis but also played a role in reducing VLDL secretion(25) and plasma TG levels, as observed with treatment.(14) More importantly, improvement in hepatic insulin sensitivity was proportional to the increase i…”
BackgroundMethodResultInfluentialSelf-citationLiver disease and diabetes: Association, pathophysiology, and management
Ahmadieh, H., & Azar, S. T. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2014.01.003 · Cited by 118
Perumpail, R. B., Wong, R. J., Ahmed, A., & Harrison, S. A. (2015) · Digestive Diseases and Sciences · doi:10.1007/s10620-015-3821-7 · Cited by 111
“A recent study showed that the primary chemopreventive effects of metformin are secondary to down-regulating the expression of several lipogenic enzymes and de novo lipogenesis [39].”
Background
Metadata
- Authors
- Belfort, R., Harrison, S. A., Brown, K., Darland, C., Finch, J., Hardies, J., Balas, B., Gastaldelli, A., Tio, F., Pulcini, J., Berria, R., Ma, J. Z., Dwivedi, S., Havranek, R., Fincke, C., DeFronzo, R., Bannayan, G. A., Schenker, S., & Cusi, K.
- Affiliations
- The University of Texas at San Antonio Health Science Center (US)
- Brooke Army Medical Center (US)
- South Texas Veterans Health Care System (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-11-30
- Volume
- 355
- Issue
- 22
- Pages
- 2297-2307
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2103156933
- Cited by
- 1,827
- References
- 38
- Citations by year
- 2026: 44 · 2025: 73 · 2024: 83 · 2023: 78 · 2022: 84 · 2021: 93 · 2020: 73 · 2019: 74 · 2018: 70 · 2017: 93 · 2016: 98 · 2015: 106 · 2014: 92 · 2013: 87 · 2012: 85
- FWCI
- 91.90
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- INFM-OAR (INFN Catania) (submittedVersion, other-oa)
- Funders
- National Center for Research Resources (M01RR01346, M01RR001346)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Keywords
- alcoholic steatohepatitis, thiazolidinediones, insulin resistance, hypocaloric diet, hepatic steatosis, hepatic insulin sensitivity, necroinflammation, liver fibrosis, glucose tolerance, type 2 diabetes, impaired glucose tolerance, hepatic aminotransferases, drug safety, adverse effects
- MeSH terms
- Pioglitazone, Blood Glucose, Combined Modality Therapy, Diabetes Mellitus, Type 2, Double-Blind Method, Fatty Liver, Female, Hepatitis, Humans, Hypoglycemic Agents, Insulin, Insulin Resistance, Liver, Liver Cirrhosis, Male, Middle Aged, Necrosis, Glucose Intolerance, Caloric Restriction, Thiazolidinediones
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.